222 related articles for article (PubMed ID: 29927386)
1. Phase I study on safety and pharmacokinetics of a novel influenza endonuclease inhibitor, AL-794 (JNJ-64155806), following single- and multiple-ascending doses in healthy adults.
Kakuda TN; Yogaratnam J; Rito J; Boyce M; Mitchell T; Gupta K; Symons JA; Chanda S; Van Remoortere P; Fry J
Antivir Ther; 2018; 23(7):555-566. PubMed ID: 29927386
[TBL] [Abstract][Full Text] [Related]
2. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study.
Yogaratnam J; Rito J; Kakuda TN; Fennema H; Gupta K; Jekle CA; Mitchell T; Boyce M; Sahgal O; Balaratnam G; Chanda S; Van Remoortere P; Symons JA; Fry J
J Infect Dis; 2019 Jan; 219(2):177-185. PubMed ID: 30053042
[TBL] [Abstract][Full Text] [Related]
4. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects.
Saisho Y; Ishibashi T; Fukuyama H; Fukase H; Shimada J
Antivir Ther; 2017; 22(4):313-323. PubMed ID: 27805571
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.
Koshimichi H; Ishibashi T; Kawaguchi N; Sato C; Kawasaki A; Wajima T
Clin Drug Investig; 2018 Dec; 38(12):1189-1196. PubMed ID: 30288682
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers.
Kakuda TN; Yogaratnam JZ; Westland C; Gane EJ; Schwabe C; Vuong J; Patel M; Snoeys J; Talloen W; Lenz O; Fry J; Chanda S; van Remoortere P
Antivir Ther; 2021; 26(1-2):13-24. PubMed ID: 35485346
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects.
Vandenbossche J; Jessner W; van den Boer M; Biewenga J; Berke JM; Talloen W; De Zwart L; Snoeys J; Yogaratnam J
Adv Ther; 2019 Sep; 36(9):2450-2462. PubMed ID: 31267367
[TBL] [Abstract][Full Text] [Related]
9. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects.
Huntjens DRH; Ouwerkerk-Mahadevan S; Brochot A; Rusch S; Stevens M; Verloes R
Clin Pharmacokinet; 2017 Nov; 56(11):1331-1342. PubMed ID: 28238203
[TBL] [Abstract][Full Text] [Related]
11. Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):39-52. PubMed ID: 26581327
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers.
Pawsey S; Wood M; Browne H; Donaldson K; Christie M; Warrington S
Drugs R D; 2016 Jun; 16(2):181-91. PubMed ID: 26987975
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Learnings from a Double-Blind, Randomized, Placebo-Controlled, Sequential Group First-in-Human Study of the TRPV1 Antagonist, JNJ-38893777, in Healthy Men.
Manitpisitkul P; Mayorga A; Shalayda K; De Meulder M; Romano G; Jun C; Moyer JA
Clin Drug Investig; 2015 Jun; 35(6):353-63. PubMed ID: 25894894
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension: A Phase 1, Randomized, Double-Blind, Single- and Multiple-Dose Study.
Ismat FA; Usansky HH; Villa R; Zou J; Teper A
Adv Ther; 2022 Nov; 39(11):5144-5157. PubMed ID: 36070132
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteers.
Brennan BJ; Davies B; Cirrincione-Dall G; Morcos PN; Beryozkina A; Chappey C; Aceves Baldó P; Lennon-Chrimes S; Rayner CR
Antimicrob Agents Chemother; 2012 Sep; 56(9):4729-37. PubMed ID: 22733065
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Mohamed MF; Camp HS; Jiang P; Padley RJ; Asatryan A; Othman AA
Clin Pharmacokinet; 2016 Dec; 55(12):1547-1558. PubMed ID: 27272171
[TBL] [Abstract][Full Text] [Related]
17. Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants.
Bundrant L; Hunt TL; Banks P; Gopinathan S; Boehm KA; Kassler-Taub K; Tyle P; Wilson A; Warner C; Wason S
Clin Ther; 2021 Jun; 43(6):1029-1050. PubMed ID: 34108079
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and pharmacokinetics of single and multiple ascending Oral doses of DA-8010 in healthy subjects: First-in-human phase I study.
Lee DY; Lee MJ; Ryu C; Lee H; Brooks A
Pharmacol Res Perspect; 2023 Feb; 11(1):e01040. PubMed ID: 36734627
[TBL] [Abstract][Full Text] [Related]
19. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
